β-Casein hydrolysate generated by the cell envelope-associated proteinase of Lactobacillus delbrueckii ssp. lactis CRL 581 protects against trinitrobenzene sulfonic acid-induced colitis in mice.
- 2012-03
- Journal of Dairy Science 95(3)
- M. B. E. Turbay
- A. LeBlanc
- G. Perdigón
- G. S. D. Giori
- E. Hebert
- PubMed: 22365194
- DOI: 10.3168/jds.2011-4735
Abstract
Lactobacillus delbrueckii ssp. lactis CRL 581, a thermophilic lactic acid bacterium used as a starter culture for the manufacture of several fermented dairy products, possesses an efficient proteolytic system that is able to release a series of potentially bioactive peptides (i.e., antihypertensive and phosphopeptides) from α- and β-caseins. Considering the potential beneficial health effects of the peptides released by L. delbrueckii ssp. lactis CRL 581 from milk proteins, the aim of this work was to analyze the anti-mutagenic and anti-inflammatory properties of the casein hydrolysates generated by the cell envelope-associated proteinase of this bacterium. The ability of α- and β-casein hydrolysates to suppress the mutagenesis of a direct-acting mutagen 4-nitroquinoline-N-oxide on Salmonella typhimurium TA 98 and TA 100 increased concomitantly with the time of casein hydrolysis. The anti-inflammatory effect of the β-casein hydrolysate was evaluated using a trinitrobenzene sulfonic acid (TNBS)-induced Crohn's disease murine model. The hydrolysate was administered to mice 10 d before the intrarectal inoculation of TNBS. The mice that received β-casein hydrolysate previously to TNBS showed decreased mortality rates, faster recovery of initial body weight loss, less microbial translocation to the liver, decreased β-glucuronidase and myeloperoxidase activities in the gut, and decreased colonic macroscopic and microscopic damage compared with the animals that did not receive this hydrolysate. In addition, β-casein hydrolysate exerted a beneficial effect on acute intestinal inflammation by increased interleukin 10 and decreased IFN-γ production in the gut. Our findings are consistent with the health-promoting attributes of the milk products fermented by L. delbrueckii ssp. lactis CRL 581 and open up new opportunities for developing novel functional foods.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Lactobacillus delbrueckii | Faster Recovery of Body Weight | Beneficial | Moderate |
Lactobacillus delbrueckii | Increased Interleukin-10 Production in the Gut | Beneficial | Moderate |
Lactobacillus delbrueckii | Reduced Gut IFN-γ Production | Beneficial | Large |
Lactobacillus delbrueckii | Reduced Microbial Translocation | Beneficial | Moderate |
Lactobacillus delbrueckii | Reduced Mortality Rate | Beneficial | Moderate |
Lactobacillus lactis LI-23 | Accelerated Weight Loss Recovery | Beneficial | Moderate |
Lactobacillus lactis LI-23 | Improved Macroscopic Colonic Damage | Beneficial | Moderate |
Lactobacillus lactis LI-23 | Increased IL-10 Production | Beneficial | Moderate |
Lactobacillus lactis LI-23 | Reduced Beta-Glucuronidase Activity | Beneficial | Moderate |
Lactobacillus lactis LI-23 | Reduced Colonic Microscopic Damage | Beneficial | Moderate |
Lactobacillus lactis LI-23 | Reduced Gut IFN-γ Production | Beneficial | Large |
Lactobacillus lactis LI-23 | Reduced Microbial Translocation to the Liver | Beneficial | Moderate |
Lactobacillus lactis LI-23 | Reduced Mortality Rate | Beneficial | Moderate |
Lactobacillus lactis LI-23 | Reduced Myeloperoxidase Activity | Beneficial | Moderate |
Lactobacillus lactis LLa61 | Faster Recovery of Body Weight | Beneficial | Moderate |
Lactobacillus lactis LLa61 | Increased IL-10 Production | Beneficial | Moderate |
Lactobacillus lactis LLa61 | Reduced Colonic Oxidative Damage | Beneficial | Large |
Lactobacillus lactis LLa61 | Reduced Interferon-Gamma Production | Beneficial | Moderate |
Lactobacillus lactis LLa61 | Reduced Microbial Translocation to the Liver | Beneficial | Moderate |
Lactobacillus lactis LLa61 | Reduced Mortality Rate | Beneficial | Moderate |